After a study is completed, the Trial Master File is archived to preserve essential trial documentation for regulatory review and future audits. The TMF contains records that demonstrate the study was conducted in accordance with good clinical practice and that data were generated and managed properly. Archiving ensures the documents are securely stored, remain retrievable for the required retention period, and are protected from loss or unauthorized access. Deleting the TMF immediately would erase critical evidence and violate retention obligations. Publicly posting the TMF is inappropriate due to confidentiality and data protection concerns. Keeping the TMF only on one device increases the risk of loss or damage and does not meet best practices for durability and compliance; archiving uses a secure repository with backups, access controls, and defined retention periods.

Questions are built around realistic clinical trial scenarios that require you to determine the best action, decision, or interpretation given regulatory and ethical requirements. This structure tests your ability to apply guidelines to a concrete situation, mirroring the decisions a study team faces in daily practice. The scenario format aligns with the exam’s goal of assessing applied knowledge of GCP, trial conduct, and participant safety, rather than simple memorization. Formats like true/false, short answer, or fill-in-the-blank don’t provide the same depth of applied judgment. True/false is limited to binary choices and can encourage guessing; short answer and fill-in-the-blank emphasize recall and free-form response rather than selecting the best option in a defined scenario. With scenario-based questions, you evaluate factors such as consent validity, safety reporting timelines, protocol adherence, data integrity, and regulatory obligations within the context presented.

The primary endpoint is the main outcome the study is designed to assess to determine whether the treatment has a meaningful effect. It is the central result used to judge efficacy and is specified before data collection so the study can be properly powered to detect a difference. This outcome drives the statistical analysis and is the primary basis for concluding whether the treatment works. Time to trial completion is about logistics and duration, not the treatment’s effect. Total sample size is a planning/design parameter, not an outcome measured to judge efficacy. An observed adverse event is a safety observation and, while important, is typically considered a secondary endpoint or part of safety analyses rather than the primary measure of treatment effect. For example, in a cancer trial the primary endpoint might be progression-free survival, while adverse events would be analyzed separately for safety.

Source data are the original records or certified copies that contain the data used to support the trial findings. They are the first place where information about a participant is recorded—such as patient charts, hospital records, lab worksheets, or electronic files that originate from the source document—before it’s entered into the case report forms. Regulators require that data in the study be traceable back to these source documents, and you verify this by comparing the CRF data to the source data to ensure accuracy and integrity. The study protocol describes how the trial is run, the budget covers finances, and the final publication presents the results, not the raw data used to derive them.